ADMA BIOLOGICS INC (ADMA) Stock Fundamental Analysis
USA - NASDAQ:ADMA - US0008991046 - Common Stock
14.07 USD
-0.59 (-4.02%)
14.05 USD
-0.02 (-0.14%)
Overall ADMA gets a fundamental rating of 6 out of 10. We evaluated ADMA against 536 industry peers in the Biotechnology industry. While ADMA has a great health rating, its profitability is only average at the moment. ADMA has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! These ratings could make ADMA a good candidate for value and growth investing.
1. Profitability
1.1 Basic Checks
In the past year ADMA was profitable.
ADMA had a positive operating cash flow in the past year.
In the past 5 years ADMA reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: ADMA reported negative operating cash flow in multiple years.
1.2 Ratios
ADMA has a better Return On Assets (37.42%) than 98.88% of its industry peers.
ADMA's Return On Equity of 52.45% is amongst the best of the industry. ADMA outperforms 98.69% of its industry peers.
ADMA has a better Return On Invested Capital (25.43%) than 98.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 37.42% | ||
| ROE | 52.45% | ||
| ROIC | 25.43% |
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 44.06%, ADMA belongs to the best of the industry, outperforming 98.51% of the companies in the same industry.
Looking at the Operating Margin, with a value of 32.82%, ADMA belongs to the top of the industry, outperforming 97.39% of the companies in the same industry.
With a decent Gross Margin value of 53.00%, ADMA is doing good in the industry, outperforming 76.12% of the companies in the same industry.
In the last couple of years the Gross Margin of ADMA has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 32.82% | ||
| PM (TTM) | 44.06% | ||
| GM | 53% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so ADMA is creating value.
The number of shares outstanding for ADMA has been increased compared to 1 year ago.
The number of shares outstanding for ADMA has been increased compared to 5 years ago.
The debt/assets ratio for ADMA has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 14.96 indicates that ADMA is not in any danger for bankruptcy at the moment.
ADMA has a better Altman-Z score (14.96) than 88.43% of its industry peers.
ADMA has a debt to FCF ratio of 1.12. This is a very positive value and a sign of high solvency as it would only need 1.12 years to pay back of all of its debts.
ADMA has a Debt to FCF ratio of 1.12. This is amongst the best in the industry. ADMA outperforms 94.40% of its industry peers.
ADMA has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of ADMA (0.18) is worse than 67.72% of its industry peers.
Although ADMA does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 1.12 | ||
| Altman-Z | 14.96 |
ROIC/WACC2.64
WACC9.64%
2.3 Liquidity
A Current Ratio of 5.33 indicates that ADMA has no problem at all paying its short term obligations.
ADMA has a Current ratio (5.33) which is comparable to the rest of the industry.
ADMA has a Quick Ratio of 2.78. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ADMA (2.78) is worse than 64.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.33 | ||
| Quick Ratio | 2.78 |
3. Growth
3.1 Past
ADMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 285.71%, which is quite impressive.
Looking at the last year, ADMA shows a very strong growth in Revenue. The Revenue has grown by 43.58%.
Measured over the past years, ADMA shows a very strong growth in Revenue. The Revenue has been growing by 70.84% on average per year.
EPS 1Y (TTM)285.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.69%
Revenue 1Y (TTM)43.58%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%13.8%
3.2 Future
Based on estimates for the next years, ADMA will show a very strong growth in Earnings Per Share. The EPS will grow by 32.01% on average per year.
The Revenue is expected to grow by 22.46% on average over the next years. This is a very strong growth
EPS Next Y15.6%
EPS Next 2Y34.24%
EPS Next 3Y36.01%
EPS Next 5Y32.01%
Revenue Next Year19.9%
Revenue Next 2Y22.93%
Revenue Next 3Y25%
Revenue Next 5Y22.46%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 26.06, which means the current valuation is very expensive for ADMA.
ADMA's Price/Earnings ratio is rather cheap when compared to the industry. ADMA is cheaper than 93.66% of the companies in the same industry.
ADMA's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.90.
With a Price/Forward Earnings ratio of 15.62, ADMA is valued correctly.
Based on the Price/Forward Earnings ratio, ADMA is valued cheaper than 94.22% of the companies in the same industry.
ADMA's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.36.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.06 | ||
| Fwd PE | 15.62 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ADMA is valued cheaply inside the industry as 93.66% of the companies are valued more expensively.
ADMA's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ADMA is cheaper than 92.72% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 51.17 | ||
| EV/EBITDA | 21.29 |
4.3 Compensation for Growth
ADMA's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of ADMA may justify a higher PE ratio.
ADMA's earnings are expected to grow with 36.01% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.67
PEG (5Y)N/A
EPS Next 2Y34.24%
EPS Next 3Y36.01%
5. Dividend
5.1 Amount
No dividends for ADMA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
14.07
-0.59 (-4.02%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners89.29%
Inst Owner Change0%
Ins Owners2.35%
Ins Owner Change-0.83%
Market Cap3.36B
Analysts82
Price Target29.64 (110.66%)
Short Float %6.87%
Short Ratio4.81
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-16.56%
Min EPS beat(2)-31.17%
Max EPS beat(2)-1.96%
EPS beat(4)1
Avg EPS beat(4)-7.13%
Min EPS beat(4)-31.17%
Max EPS beat(4)13.12%
EPS beat(8)4
Avg EPS beat(8)-13.7%
EPS beat(12)6
Avg EPS beat(12)-7.65%
EPS beat(16)9
Avg EPS beat(16)-4.75%
Revenue beat(2)0
Avg Revenue beat(2)-2.91%
Min Revenue beat(2)-3.31%
Max Revenue beat(2)-2.51%
Revenue beat(4)2
Avg Revenue beat(4)1.84%
Min Revenue beat(4)-3.31%
Max Revenue beat(4)10.99%
Revenue beat(8)6
Avg Revenue beat(8)4.93%
Revenue beat(12)10
Avg Revenue beat(12)6.13%
Revenue beat(16)14
Avg Revenue beat(16)6.66%
PT rev (1m)0%
PT rev (3m)-1.46%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-8%
EPS NY rev (1m)-1.02%
EPS NY rev (3m)-14.79%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.53%
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)-1.76%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.06 | ||
| Fwd PE | 15.62 | ||
| P/S | 7.08 | ||
| P/FCF | 51.17 | ||
| P/OCF | 43.77 | ||
| P/B | 8.43 | ||
| P/tB | 8.52 | ||
| EV/EBITDA | 21.29 |
EPS(TTM)0.54
EY3.84%
EPS(NY)0.9
Fwd EY6.4%
FCF(TTM)0.27
FCFY1.95%
OCF(TTM)0.32
OCFY2.28%
SpS1.99
BVpS1.67
TBVpS1.65
PEG (NY)1.67
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 37.42% | ||
| ROE | 52.45% | ||
| ROCE | 32.19% | ||
| ROIC | 25.43% | ||
| ROICexc | 31.27% | ||
| ROICexgc | 31.6% | ||
| OM | 32.82% | ||
| PM (TTM) | 44.06% | ||
| GM | 53% | ||
| FCFM | 13.84% |
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
F-Score5
Asset Turnover0.85
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 1.12 | ||
| Debt/EBITDA | 0.45 | ||
| Cap/Depr | 140.25% | ||
| Cap/Sales | 2.34% | ||
| Interest Coverage | 13.21 | ||
| Cash Conversion | 46.9% | ||
| Profit Quality | 31.4% | ||
| Current Ratio | 5.33 | ||
| Quick Ratio | 2.78 | ||
| Altman-Z | 14.96 |
F-Score5
WACC9.64%
ROIC/WACC2.64
Cap/Depr(3y)120.67%
Cap/Depr(5y)186.15%
Cap/Sales(3y)4.32%
Cap/Sales(5y)11.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)285.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.69%
EPS Next Y15.6%
EPS Next 2Y34.24%
EPS Next 3Y36.01%
EPS Next 5Y32.01%
Revenue 1Y (TTM)43.58%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%13.8%
Revenue Next Year19.9%
Revenue Next 2Y22.93%
Revenue Next 3Y25%
Revenue Next 5Y22.46%
EBIT growth 1Y85.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year49.25%
EBIT Next 3Y41.34%
EBIT Next 5Y36.1%
FCF growth 1Y227.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y285.06%
OCF growth 3YN/A
OCF growth 5YN/A